Kyprolis 60 mg powder for solution for infusion clinical trials
9 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) - ALUMMINATE RRMM
This study is testing a new medicine, Alnuctamab, for people in the UK with multiple myeloma whose cancer has come back or isn't responding to other treatments. Researchers want to see if Alnuctamab works better and is safer than current treatments, aiming to stop the cancer from growing for longer.
For: Relapsed and/or Refractory Multiple MyelomaGermany · Italy · Sweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
ISKPD-IFM2018-03-Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma
This study is testing a new combination of medicines for people with multiple myeloma that has come back or hasn't responded to previous treatments. It aims to see how well these medicines work together to reduce the amount of cancer in the body.
For: Multiple MyelomaFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressive patients with multiple myeloma after a first-line therapy
This study compares a special stem cell treatment to standard care for people with multiple myeloma that has come back or worsened after their first treatment. It aims to see which approach helps people live longer and feel better over five years.
For: multiple myelomaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
KRd consolidation in myeloma patients with a positive PET-CT after standard first line treatment. A phase II study
This study looks at a new treatment combination called KRd for people with multiple myeloma whose scans still show some active cancer after their first treatment. We want to see if KRd can help these patients achieve better results, specifically if their scans become completely clear.
For: Multiple MyelomaDenmark · Norway - AuthorisedTherapeutic exploratory (Phase II)
Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - "Time is Kidney in the Treatment of myeloma Cast nephropathy" The TIKTAC phase II trial (Pilot-study)
This study looks at a new combination of medicines (DCPD) for people with multiple myeloma whose kidneys are not working well. It aims to see if kidney function improves, or if people needing dialysis can stop needing it, after four cycles of treatment.
For: Multiple myelomaAustria - AuthorisedTherapeutic confirmatory (Phase III)
MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM
This study is looking at new ways to treat multiple myeloma, a type of blood cancer, in people under 66. It's testing if different treatment plans can better reduce the cancer to very low levels before further treatment. The aim is to find out which approaches work best for patients.
For: Multiple MyelomaBelgium · France - AuthorisedTherapeutic exploratory (Phase II)
Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple myeloma (MM)
This study is looking at new ways to treat or prevent multiple myeloma, a type of blood cancer. Researchers are testing medicines to see if they can stop the cancer from getting worse in people who have early forms of the disease or are already being treated.
For: Multiple MyelomaIceland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as pre transplant INDUCTION and post transplant consolidation or continuous treatment with CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 cycles) without transplant, all followed by MAINTENANCE with LENALIDOMIDE (R) versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT
This study looks at new ways to treat newly diagnosed multiple myeloma. It compares different drug combinations, with or without a stem cell transplant, followed by ongoing treatment to see which works best at keeping the cancer under control. It aims to find better treatments for patients.
For: NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANTItaly - AuthorisedTherapeutic confirmatory (Phase III)
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
This study is testing new treatments for a type of blood cancer called multiple myeloma that has come back or isn't responding to previous treatments. It compares new drugs, Linvoseltamab alone or with Carfilzomib, against standard treatments to see how well they work and if they are safe.
For: Relapsed Refractory Multiple MyelomaGreece · Spain · Poland